Trial Profile

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 29 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary)
Indications Brain metastases; Neuroendocrine carcinoma
Focus Therapeutic Use

04 Jun 2024 Trial design testing the benefit of adding atezolizumab to induction P/E as well as the role of adding maintenance atezolizumab after induction P/E plus atezolizumab were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
19 Jan 2024 Planned End Date changed from 1 Oct 2028 to 1 Oct 2031.
06 Jan 2024 Planned End Date changed from 31 Oct 2024 to 1 Oct 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com